CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
MLN0128drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02514824
NCT02514824Phase 2Completed
CompareCT.gov

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute·interventional·Posted Aug 4, 2015·Updated Dec 29, 2020

In Brief

A Phase 2 clinical trial evaluating MLN0128 for Merkel Cell Carcinoma. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. \- The name of the study intervention involved in this study is: MLN0128.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMerkel Cell Carcinoma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 4, 2015
Enrollment StartOct 1, 2015
Primary CompletionApr 1, 2017
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.9 years ago

Interventions

MLN0128drug

Investigational mTOR kinase inhibitor